Table 5.
Association Between Blood Angiogenic Biomarkers at Baseline, Their Changes at 8 Hours and at Day 1 After Cediranib Treatment With Radiographic Progression of Disease, and Mortality in Patients With Recurrent Glioblastoma
| Biomarker | Pretreatment Measurement |
Change at 8 Hours |
Mortality |
Change at Day 1 |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression |
Mortality |
Progression |
Progression |
Mortality |
||||||||||||||
| Estimate | 95% CI | No. of Observations | Estimate | 95% CI | No. of Observations | Estimate | 95% CI | No. of Observations | Estimate | 95% CI | No. of Observations | Estimate | 95% CI | No. of Observations | Estimate | 95% CI | No. of Observations | |
| Plasma PlGF | −11 | 66 to 130 | 30 | 21 | −48 to 182 | 30 | −22 | −67 to 85 | 30 | −47 | −79 to 32 | 30 | −37 | −67 to 20 | 30 | −52 | −76 to −5 | 30 |
| P | .80 | .66 | .56 | .17 | .14 | .025 | ||||||||||||
| Plasma bFGF | −16 | −33 to 6 | 30 | −13 | −29 to 7 | 30 | −16 | −41 to 20 | 30 | −15 | −39 to 17 | 30 | −14 | −43 to 29 | 30 | −35 | −56 to −2 | 30 |
| P | .18 | .21 | .34 | .32 | .47 | .040 | ||||||||||||
| Plasma MMP-2 | 74 | −1 to 206 | 25 | −20 | −52 to 36 | 25 | 351 | 20 to 1,951 | 25 | 310 | 12 to 1,403 | 25 | 186 | −22 to 946 | 25 | 127 | −38 to 724 | 25 |
| P | .057 | .41 | .020 | .031 | .094 | .19 | ||||||||||||
| Urinary MMP-9/NGAL activity | 0 | −15 to 18 | 12 | 2 | −13 to 20 | 12 | 14 | −14 to 50 | 11 | 51 | −7 to 144 | 11 | 664 | 57 to 3,620 | 11 | 40 | −25 to 163 | 11 |
| P | .97 | .81 | .35 | .059 | .0022 | .32 | ||||||||||||
NOTE. Data are shown as estimates of the association with PFS or OS (with 95% CIs), the No. of observations, and P values for the likelihood ratio test. Except for urinary protein activity, the estimates are percent increases of the hazard ratio (decreases, for negative estimates) corresponding to a doubling of the biomarker value. For urinary proteins the estimates are percent increases of the hazard ratio (decreases, for negative estimates) corresponding to an increase of the marker level by one category. Statistically significant correlations are marked by asterisks. The changes were modeled using measurements at a given time point and adjusting for baseline levels. Bold font indicates decrease.
Abbreviations: PlGF, placental growth factor; bFGF, basic fibroblast growth factor; MMP, matrix metalloproteinase; NGAL, neutrophil gelatinase-associated lipocalin.